In melanoma cases, it has been reported that apigenin activates the cleaved caspase-3 and PARP expression sites; downregulates Twist1, MMP-2/9, VEGF, p-mTOR, ERK1/2 proteins, and p-AKT; and deactivate FAK/ERK1/2 pathways [37]. This evidence concerns the gene MAPK3 and melanoma.